Specifically recognizes and binds N6-methyladenosine -containing mRNAs, and regulates their stability . M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing . Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT complex . The YTHDF paralogs share m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation . Required to facilitate learning and memory formation in the hippocampus by binding to m6A-containing neuronal mRNAs . Acts as a regulator of axon guidance by binding to m6A-containing ROBO3 transcripts . Acts as a negative regulator of antigen cross-presentation in myeloid dendritic cells . In the context of tumorigenesis, negative regulation of antigen cross-presentation limits the anti-tumor response by reducing efficiency of tumor-antigen cross-presentation . Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues: polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation . The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules .

YTH domain-containing family protein 1 (Dermatomyositis associated with cancer putative autoantigen 1 homolog) (DACA-1 homolog)

p59326

Human,Mouse,Rat

WB,IP

WB 1:1000
IP 1:20-1:50

~61 kD

Rabbit

50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.

Store at -20°C. Stable for 12 months from date of receipt.